General Updates

' GRANULES Date: October23,2026 National StockExchange ofIndiaLimited BSE Limited Symbol: NSE: GRANULES: BSE: 532482 Dear Sir, Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015-Incorporation ofWholly Owned Foreign Subsidiary Pursuant to Regulation 30 read with Schedule III ofthe SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the applicable SEBI Circular, we wish to inform youthatthe Company has incorporated a wholly owned foreign subsidiary in the name of "TRITON FARMACEUTICA S.A. de C.V. in Mexico. In terms of the Listing Regulations read with the SEBI Circular No SEBI/HO/CFD/CFD- PoDl/P/CHU2023/123 dated July 13, 2023 on Disclosure of material events/information, we are furnishing herewith the details inthe enclosed Annexures respectively. Kindlytake the above information onrecord. For GRANULES INDIA LIMITED CHAITANYA TUMMALA (COMPANY SECRETARY & COMPLIANCE OFFICER) Encl: Annexure REGISTEREDOFFSCE GranulesIndiaLimited CIN:L2l»110TG1991PLC012Z+71 15'*'Floor, GranulesTower, BotanicalGardenRoad, Kondapur, Hyderabad-500084,Telangana, India www.granu§esindia.com ContactUs:Tel: +91A0690A3500 I Fax:+91-40-231151A5 I mail@granulesindia.com :GRANULES Annexure I Disclosure under Part A Para A(i) ofSchedule III readwith Regulation 30 ofthe SEBI iListin2Obligation and Disclosure Requirements) Regulations.2015 S. No. Particulars Description 1. Nameofthetargetentity,details in brief TRITON FARMACEUTICA, S.A. de C.V. suchas size,turnoveretc. It is s newly incorporated Company in the country of Mexico and has not started its business. Authorized Sllares: 4,50,000 Shares ofMXN 10.00each 2. Whether the acquisition would fall within Upon incorporation of TRIT()N related party transaction(s) and whether FARMACEUTICA, S.A. de C.V., it became the promoter/ promoter group/ group a related partyto theCompany. companies have any interest in the entity The Promoter& PromoterGroupoflthe being acquired. If yes, the nature of Companydonothaveany interest in the interest and details thereof and whether entity incorporated. the same isdone at"arms-length" 3. The industry to which the entity being Pharmaceuticals acquired 4. Ohiects and impacts ofacquisition The Company IS being incorporated to (including butnot limited to, disclosure of manufacture, promote, sale and distribute reasons foracquisition oftargetentity, if pharmaceuticals and other related its business is outside themain line of product(s) in country ofMexico. business ofthe listedentity) 5. Briefdetailsofany governmental or Not applicable regulatory approvals required for the acquisition 6. Indicativetimeperiod forcompletionof Notapplicable theacquisition 7. Nature ofconsideration - whether cash Notapplicable consideration or share swap and details of the same 8. Cost ofacquisition orthe price at which Notapplicable the shares are acquired 9. Percentage ofshareholding/control 100% acquired and/or number ofshares acquired 10. Briefbackground about the entity Brief: Incorporated as Wholly owned foreign acquired in terms ofproducts/line of subsidiaryoftheCompany in Mexico business acquired, dateofincorporation, history ofthe last 3 yearsturnover, Dateofincorporation: 22 October2026 country in which the acquired entity has History/ 'l`urnovcr: Not Applicable (Yet to presence and any othersignificant commencebusinessoperations) information (in brief) °\_Countyofincorporation: Mexico . -I . . ContactUs=TeI:+91no69016500 I Fax:+91-$0-231151A5 I malI@granuleslndla.com www.granulesindia.com